Cellular selenium and PGJ2 metabolism

细胞硒和 PGJ2 代谢

基本信息

项目摘要

Understanding the anti-inflammatory and pro-resolving functions of micronutrient selenium (Se) incorporated as the 21st amino acid, selenocysteine (Sec), into selenoproteins may hold the key to controlling gastrointestinal (GI) homeostasis in patients with inflammatory bowel disease (IBD). Despite advances, complete mucosal healing remains a difficult treatment target for many patients with IBD. Localized response to injury involves first responders, polymorphonuclear cells (neutrophils; PMNs), and macrophages that not only display an inflammatory phenotype, but also aid in resolving inflammation via efferocytosis of apoptotic PMNs, to initiate a cascade of pro-resolution events involving metabolic reprogramming. We have demonstrated an essential role for selenoproteins in effectively shunting pathways of arachidonic acid (ARA) metabolism in macrophages to effect resolution by skewing macrophage polarization towards an anti-inflammatory/pro-resolutory (M2) phenotype. Selenoprotein-dependent differential modulation of transcription factors, nuclear factor (NF)-κB and peroxisome proliferator activated receptor (PPAR)-γ, led to eicosanoid class switching resulting in decreased cyclooxygenase (COX)-derived pro-inflammatory prostaglandin E2 (PGE2) and high PGD2 and its anti-inflammatory and pro-resolutory cyclopentenone prostaglandins (CyPGs) metabolites, ∆12-prostaglandin J2 and 15-deoxy-∆12,14-PGJ2, in three models of GI injury involving chemical injury with dextran sodium sulfate, enteric infection with bacterium Citrobacter rodentium and helminthic parasite, Nippostrongylus brasiliensis. In these models, macrophage selenoprotein expression was key to mitigating inflammation and increasing the polarization of classically activated (M1) to pro-resolving alternatively activated (M2)-like cells that was dependent on CyPG production suggesting resolution. Our studies led us to a selenoprotein, SelenoW, a highly expressed selenoprotein in macrophages in response to dietary Se supply. Apart from its function in cell cycle regulation, the role of SelenoW in GI inflammation and resolution is not well understood. Clinical data indicated that SelenoW levels in inflamed colonic tissue of ulcerative colitis patients were decreased along with PGD2 levels compared to healthy controls and those in active remission, respectively. Guided by exciting feasibility data, we hypothesize that regulation of SelenoW expression by dietary Se and/or other transcriptional mechanisms, mediated by CyPGs, may hold a key to increasing pro-resolution mechanisms to ultimately effect mucosal healing from GI injury. We will test the hypothesis in murine models lacking SelenoW to: 1) Examine the role of SelenoW in resolution of GI inflammation; 2) Examine the role of SelenoW in the interaction of macrophages and PMNs during resolution of inflammation; and 3) Examine the role of SelenoW in metabolic adaptation during resolution of inflammation. Successful completion of these studies will provide new information highlighting the interplay between specific selenoproteins and pathways of resolution of inflammation, essential to increase our understanding of the role of dietary Se in optimal gut health.
了解微量营养素硒(Se)作为第21个氨基酸--硒半胱氨酸(Sec)--在硒蛋白中的抗炎和促分解功能,可能是控制炎症性肠病(IBD)患者胃肠(GI)内环境平衡的关键。尽管取得了进展,但对于许多IBD患者来说,完全的粘膜愈合仍然是一个困难的治疗目标。对损伤的局部反应涉及第一反应者、中性粒细胞(PMN)和巨噬细胞,它们不仅表现出炎症表型,而且通过吞噬凋亡的PMN来帮助化解炎症,从而启动一系列涉及代谢重编程的促分解事件。我们已经证明了硒蛋白在有效地分流巨噬细胞中花生四烯酸(ARA)代谢途径以通过将巨噬细胞极化偏向抗炎/支持(M2)表型来影响分辨率方面发挥了重要作用。在三种胃肠道损伤模型中,依赖于硒蛋白的转录因子(核因子-κB和过氧化物酶体增殖物激活受体-γ)的差异调节导致二十烷类化合物的转换,导致环氧合酶(COX)衍生的促炎前列腺素E2(PGE_2)减少和PGD_2升高,以及它的抗炎和促炎环戊酮前列腺素(CyPGs)代谢产物∆12-前列腺素J2和15-脱氧-∆12,14-PGJ2。在这些模型中,巨噬细胞硒蛋白的表达是减轻炎症和增加经典激活(M1)到前分解交替激活(M2)样细胞的极化的关键,这依赖于CyPG的产生提示分解。我们的研究将我们引向了一种硒蛋白,SelenoW,一种在巨噬细胞中高度表达的硒蛋白,对饮食中的硒供应做出反应。除了在细胞周期调节中的作用外,SelenoW在胃肠道炎症和消退中的作用还不是很清楚。临床资料表明,溃疡性结肠炎患者炎症结肠组织中的SelenoW水平和PGD2水平分别低于健康对照组和活动期缓解期患者。在令人兴奋的可行性数据的指导下,我们假设膳食Se和/或由CyPG介导的其他转录机制对SelenoW表达的调节可能是增加促分解机制的关键,从而最终影响胃肠道损伤的粘膜修复。我们将在缺乏SelenoW的小鼠模型中检验这一假设:1)研究SelenoW在胃肠道炎症消退中的作用;2)研究SelenoW在炎症消退过程中巨噬细胞和中性粒细胞相互作用中的作用;3)研究SelenoW在炎症消退过程中代谢适应中的作用。这些研究的成功完成将提供新的信息,强调特定的硒蛋白与炎症消退途径之间的相互作用,这对于增加我们对膳食硒在最佳肠道健康中的作用的理解至关重要。

项目成果

期刊论文数量(9)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

KUMBLE SANDEEP PRABHU其他文献

KUMBLE SANDEEP PRABHU的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('KUMBLE SANDEEP PRABHU', 18)}}的其他基金

Targeting Leukemia Stem Cells with Dietary Selenium
用膳食硒靶向白血病干细胞
  • 批准号:
    8666541
  • 财政年份:
    2012
  • 资助金额:
    $ 38.6万
  • 项目类别:
Targeting Leukemia Stem Cells with Dietary Selenium
用膳食硒靶向白血病干细胞
  • 批准号:
    8382905
  • 财政年份:
    2012
  • 资助金额:
    $ 38.6万
  • 项目类别:
Targeting Leukemia Stem Cells with Dietary Selenium
用膳食硒靶向白血病干细胞
  • 批准号:
    8520264
  • 财政年份:
    2012
  • 资助金额:
    $ 38.6万
  • 项目类别:
Cellular Selenium Status and PGJ2 Metabolism
细胞硒状态和 PGJ2 代谢
  • 批准号:
    7555911
  • 财政年份:
    2008
  • 资助金额:
    $ 38.6万
  • 项目类别:
Cellular Selenium Status and PGJ2 Metabolism
细胞硒状态和 PGJ2 代谢
  • 批准号:
    7893387
  • 财政年份:
    2008
  • 资助金额:
    $ 38.6万
  • 项目类别:
Transcriptional Regulaton of Pro-Inflammatory Genes by Gambogic Acid
藤黄酸对促炎基因的转录调控
  • 批准号:
    7686373
  • 财政年份:
    2008
  • 资助金额:
    $ 38.6万
  • 项目类别:
Cellular Selenium Status and PGJ2 Metabolism (PA-17-078 supplement 2017)
细胞硒状态和 PGJ2 代谢(PA-17-078 补充版 2017)
  • 批准号:
    9431725
  • 财政年份:
    2008
  • 资助金额:
    $ 38.6万
  • 项目类别:
Cellular Selenium Status and PGJ2 Metabolism
细胞硒状态和 PGJ2 代谢
  • 批准号:
    8019049
  • 财政年份:
    2008
  • 资助金额:
    $ 38.6万
  • 项目类别:
Cellular Selenium Status and PGJ2 Metabolism
细胞硒状态和 PGJ2 代谢
  • 批准号:
    8980891
  • 财政年份:
    2008
  • 资助金额:
    $ 38.6万
  • 项目类别:
Transcriptional Regulaton of Pro-Inflammatory Genes by Gambogic Acid
藤黄酸对促炎基因的转录调控
  • 批准号:
    7530649
  • 财政年份:
    2008
  • 资助金额:
    $ 38.6万
  • 项目类别:

相似海外基金

Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
  • 批准号:
    10682121
  • 财政年份:
    2023
  • 资助金额:
    $ 38.6万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10576370
  • 财政年份:
    2022
  • 资助金额:
    $ 38.6万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10387023
  • 财政年份:
    2022
  • 资助金额:
    $ 38.6万
  • 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10248409
  • 财政年份:
    2019
  • 资助金额:
    $ 38.6万
  • 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
  • 批准号:
    nhmrc : GNT1163111
  • 财政年份:
    2019
  • 资助金额:
    $ 38.6万
  • 项目类别:
    Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10462684
  • 财政年份:
    2019
  • 资助金额:
    $ 38.6万
  • 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
  • 批准号:
    398018062
  • 财政年份:
    2018
  • 资助金额:
    $ 38.6万
  • 项目类别:
    Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9308643
  • 财政年份:
    2017
  • 资助金额:
    $ 38.6万
  • 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9447149
  • 财政年份:
    2017
  • 资助金额:
    $ 38.6万
  • 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
  • 批准号:
    8893915
  • 财政年份:
    2014
  • 资助金额:
    $ 38.6万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了